Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.60 |
| ▸ | CDK1 | P06493 | 4/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | ULK1 | O75385 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284454 | 0.88 | CDK1 (0.53) | STK17ACDK1AURKAPTK2ULK1 | |
| SCHEMBL5562631 | 0.88 | AURKA (0.52) | STK17ACDK1AURKAPTK2ULK1 | |
| SCHEMBL1916571 | 0.88 | GSK3A (0.56) | STK17ACDK1AURKAPTK2GSK3A | |
| SCHEMBL1916005 | 0.84 | PRKCQ (0.54) | STK17ACDK1AURKAULK1KDR | |
| SCHEMBL25236840 | 0.84 | AURKA (0.49) | STK17ACDK1AURKAPTK2ULK1 | |
| SCHEMBL5567919 | 0.84 | AURKA (0.49) | STK17ACDK1AURKAPTK2ULK1 | |
| SCHEMBL1627493 | 0.84 | AURKA (0.52) | STK17ACDK1AURKAPTK2ULK1 | |
| SCHEMBL5566717 | 0.84 | PTK2 (0.58) | CDK1AURKAPTK2KDRCNR2 | |
| SCHEMBL30646205 | 0.84 | AURKA (0.49) | STK17ACDK1AURKAPTK2ULK1 | |
| SCHEMBL15506892 | 0.84 | AURKA (0.48) | STK17ACDK1AURKAPTK2ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | disclosed |
| EP-2332924-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-2090571-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | disclosed |
| EP-1663991-B1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | PFIZER PROD INC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-7122670-B2 | Selective synthesis of CF3-substituted pyrimidines | PFIZER INC (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1663991-A1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | Pfizer Products Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
| US-20050101620-A1 | Selective synthesis of CF3-substituted pyrimidines | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005023780-A1 | SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES | PFIZER PRODUCTS INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | STK17A 1083/4885CDK1 39/4885AURKA 1005/4885 |
| US-20050101620-A1 | Selective synthesis of CF3-substituted pyrimidines | HNRNPH3, HNRNPA3, NUDT1 | STK17A 3993/4885CDK1 541/4885AURKA 2928/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | STK17A 2304/4885CDK1 17/4885AURKA 1385/4885 |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | STK17A 1083/4885CDK1 39/4885AURKA 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.